BridgeBio Oncology Therapeutics (BBOT) Net Income towards Common Stockholders (2024 - 2026)
BridgeBio Oncology Therapeutics' Net Income towards Common Stockholders was -$56.5 million in Q2 2026, compared with $918,310 a year earlier.
Powered by 
Analysis
BridgeBio Oncology Therapeutics (BBOT) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
On a trailing twelve-month basis, BridgeBio Oncology Therapeutics' Net Income towards Common Stockholders was -$182.16 million through Jun 30, 2026; for FY2025, it was -$134.04 million.
- In earlier years, Net Income towards Common Stockholders was $7.6 million in FY2024 and -$41,692 in FY2023.
- The Q2 2026 figure marks the lowest quarterly Net Income towards Common Stockholders in data going back to Q1 2024.
- Per Business Quant data, BBOT's Net Income towards Common Stockholders in the three quarters before Q2 2026 was -$42.11 million (Q1 2026), -$38.8 million (Q4 2025) and -$44.76 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | -248.00 Mn |
| 10 | BridgeBio Oncology Therapeutics | 213.11 Mn | -1.16 Bn | - | -56.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -56.50 Mn |
| Mar 31, 2026 | -42.11 Mn |
| Dec 31, 2025 | -38.80 Mn |
| Sep 30, 2025 | -44.76 Mn |
| Jun 30, 2025 | 918,310.00 |
| Mar 31, 2025 | -487,392.00 |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.21 Mn |
| Mar 31, 2024 | 1.10 Mn |
API Access
BridgeBio Oncology Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=BBOT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "BBOT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=BBOT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();